Cited 6 times in
Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정현철 | - |
dc.contributor.author | 조재용 | - |
dc.date.accessioned | 2018-08-28T17:20:33Z | - |
dc.date.available | 2018-08-28T17:20:33Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1743-7555 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/162495 | - |
dc.description.abstract | AIM: We describe a subgroup analysis assessing the efficacy and safety of ramucirumab monotherapy in East Asian (EA) patients from the REGARD trial. METHODS: Patients with advanced gastric or gastroesophageal junction adenocarcinoma with progressive disease were randomized 2:1 to receive ramucirumab (8 mg/kg) plus best supportive care (BSC) or placebo plus BSC every 2 weeks. Post hoc subset analyses were performed on the EA and non-EA intention-to-treat populations. RESULTS: Of 355 intention-to-treat patients, 26 patients from EA were randomized to ramucirumab (n = 18) or placebo (n = 8). Median overall survival was 6.5 months in the ramucirumab arm and 4.8 months in the placebo arm (hazard ratio [HR] 0.69; 95% confidence interval [CI], 0.27-1.82) for EA patients, and 5.2 months in the ramucirumab arm and 3.8 months in the placebo arm (HR 0.78; 95% CI, 0.60-1.02) for non-EA patients. The rate of disease control was numerically higher in ramucirumab patients versus placebo; 61% versus 38% respectively for EA patients, and 48% versus 22% for non-EA patients. The incidence of grade >/=3 treatment emergent adverse events was higher in the ramucirumab arm compared to placebo (39% vs 13%). CONCLUSION: Despite limitations, this subgroup analysis suggests that ramucirumab monotherapy improves efficacy outcomes with a tolerable safety profile in EA patients with previously treated advanced gastric cancer. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Blackwell Pub. Asia | - |
dc.relation.isPartOf | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Victor C Kok | - |
dc.contributor.googleauthor | Rebecca Cheng | - |
dc.contributor.googleauthor | Yanzhi Hsu | - |
dc.contributor.googleauthor | Mauro Orlando | - |
dc.contributor.googleauthor | Charles Fuchs | - |
dc.contributor.googleauthor | Jae Yong Cho | - |
dc.identifier.doi | 10.1111/ajco.12829 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A03899 | - |
dc.relation.journalcode | J00257 | - |
dc.identifier.eissn | 1743-7563 | - |
dc.identifier.pmid | 29318751 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/abs/10.1111/ajco.12829 | - |
dc.subject.keyword | Asia | - |
dc.subject.keyword | gastric cancer | - |
dc.subject.keyword | gastrointestinal neoplasms | - |
dc.subject.keyword | ramucirumab | - |
dc.subject.keyword | vascular endothelial growth factor receptor-2 | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.alternativeName | Cho, Jae Yong | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Cho, Jae Yong | - |
dc.citation.volume | 14 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 204 | - |
dc.citation.endPage | 209 | - |
dc.identifier.bibliographicCitation | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol.14(3) : 204-209, 2018 | - |
dc.identifier.rimsid | 60076 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.